BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by ...

In terms of valuation, BioCryst Pharmaceuticals Inc’s market capitalization stands at $1.66 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company ...

BioCryst Pharmaceuticals Inc (BCRX) stock saw a modest uptick, ending the day at $7.73 which represents a slight increase of $0.11 or 1.44% from the prior close of $7.62. The stock opened at $7.58 and ...

64.4% of Immatics shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 3.3% of Immatics shares are held by insiders.

Hidden gems in the biotech sector are reshaping healthcare with breakthroughs in personalized medicine and rare disease ...

BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 and BioCryst Pharmaceuticals, Inc. (BCRX) 10-day simple moving average is 7.67. BioCryst Pharmaceuticals, Inc. (BCRX) stock price is 7.33 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioCryst Pharmaceuticals projects 2025 ORLADEYO net revenue of $515-$535 million and total revenue of $540-$560 million. BioCryst Pharmaceuticals announced its preliminary unaudited ORLADEYO ...

Check the time stamp on this data. Updated AI-Generated Signals for Biocryst Pharmaceuticals Inc. (BCRX) available here: BCRX. Type a few symbols and Take a Trial. The signals for these will appear ...

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO ...

RESEARCH TRIANGLE PARK, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue and total ...